U.S. Markets close in 49 mins

Nektar Therapeutics Jumps on Positive Results From Melanoma Treatment Study

Tony Owusu

were up 10.2% to $34.50 Monday after the company reported positive results from the clinical study of its melanoma treatment candidates. The Chicago-based company said that its two candidates, bempegaldesleukin and nivolumab, were showing positive signs in testing. The Stage IV melanoma patients enrolled in the ongoing PIVOT-02 study continue to experience both deepening and durability of response over time," said Jonathan Zalevsky, chief scientific officer at Nektar Therapeutics.